As Exclusivity Loss Looms, Merck Wins Subcutaneous Approval for Keytruda

Merck has secured FDA approval for Keytruda Qlex, a subcutaneous formulation of its blockbuster cancer drug Keytruda, which has been the world's top-selling pharmaceutical. This strategic move aims to mitigate the impact of Keytruda's patent expiry in 2028 and impending biosimilar competition by offering a more convenient, equally effective administration method for 38 cancer indications. Priced at parity with the intravenous version and available this month, Keytruda Qlex is central to Merck's lifecycle management efforts to maintain significant market share against future competitive pressures.

Analysis

Merck's recent FDA approval for Keytruda Qlex, a subcutaneous formulation of its blockbuster cancer therapy, represents a critical execution of its lifecycle management strategy ahead of the primary drug's patent expiration in 2028. Keytruda, which generated $25 billion and $29.5 billion in 2023 and 2024 respectively, faces a significant revenue threat from biosimilar competition. This new formulation aims to mitigate that risk by offering enhanced convenience—a faster administration time compared to the 30-minute infusion and availability in more accessible settings like doctors' offices. Crucially, this convenience does not come at the cost of efficacy; pivotal trial data showed a comparable overall response rate of 45% for Keytruda Qlex versus 42% for the intravenous version in non-small cell lung cancer, with similar survival outcomes. By pricing the new formulation at parity with the intravenous version, which costs nearly $11,800 for a three-week course, Merck is facilitating a seamless transition for patients and providers, aiming to convert a substantial portion of the market to the new, patent-protected product before 2028. This proactive measure significantly de-risks the impending patent cliff and is designed to help the Keytruda franchise retain a significant market share against future competition.

Key Decisions for Investors

• This FDA approval should be viewed as a significant positive catalyst for Merck (MRK), as it provides a clear and credible strategy to defend its most critical revenue stream beyond the 2028 patent cliff.
• Investors should closely monitor the adoption rate of Keytruda Qlex in upcoming quarterly earnings reports, as a rapid conversion from the intravenous version will be the primary indicator of this defensive strategy's success.
• While this development strengthens Merck's long-term position, it is prudent to continue tracking the progress of biosimilar developers, as their future pricing and market access strategies will ultimately determine the long-term erosion of the Keytruda franchise.